Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1

Haiqing Wang, Gregory M. Vath, Akane Kawamura, Caleb A. Bates, Edith Sim, Patrick E. Hanna, Carston R Wagner

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Human arylamine N-acetyltransferase 1 (NAT1) has been overexpressed in E. coli as a mutant dihydrofolic acid reductase (DHFR) fusion protein with a thrombin sensitive linker. An initial DEAE anion-exchange chromatography resulted in partial purification of the fusion protein. The fusion protein was cleaved with thrombin, and human rNAT1 was purified with a second DEAE column. A total of 8 mg of human rNAT1 from 2 l of cell culture was purified to homogeneity with this methodology. Arylamine substrate specificities were determined for human rNAT1 and hamster rNAT2. With both NATs, the second order rate constants (k cat/K mb) for p-aminobenzoic acid (PABA) and 2-aminofluorene (2-AF) were several thousand-fold higher than those for procainamide (PA), consistent with the expected substrate specificities of the enzymes. However, p-aminosalicylic acid (PAS), previously reported to be a human NAT1 and hamster NAT2 selective substrate, exhibits 20-fold higher specificity for hamster rNAT2 (k cat/K mb3410 μM -1 s -1 ) than for human rNAT1 (k cat/K mb 169.4 μM -1 s -1 ). p-aminobenzoylglutamic acid (pABglu) was acetylated 10-fold more efficiently by human rNAT1 than by hamster rNAT2. Inhibition studies of human rNAT1 and hamster rNAT2 revealed that folic acid and methotrexate (MTX) are competitive inhibitors of both the unacetylated and acetylated forms of the enzymes, with K I values in 50-300 μ range. Dihydrofolic acid (DHF) was a much poorer inhibitor of human rNAT1 than of hamster rNAT2. The combined results demonstrate that human rNAT1 and hamster rNAT2 have similar but distinct kinetic properties with certain substrates, and suggest that folic acid, at least in the non-polyglutamate form, may not have an effect on human NAT1 activity in vivo.

Original languageEnglish (US)
Pages (from-to)65-77
Number of pages13
JournalProtein Journal
Volume24
Issue number2
DOIs
StatePublished - Feb 1 2005

Fingerprint

Purification
Cricetinae
Fusion reactions
Acids
Substrates
Folic Acid
Thrombin
Aminosalicylic Acid
4-Aminobenzoic Acid
Procainamide
Proteins
Cats
Enzymes
Substrate Specificity
Chromatography
Cell culture
Methotrexate
Escherichia coli
Anions
Rate constants

Keywords

  • Arylamine N-acetyltransferase
  • Dihydrofolate
  • Folate
  • Methotrexate
  • NAT
  • p-aminobenzoic acid

Cite this

Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1. / Wang, Haiqing; Vath, Gregory M.; Kawamura, Akane; Bates, Caleb A.; Sim, Edith; Hanna, Patrick E.; Wagner, Carston R.

In: Protein Journal, Vol. 24, No. 2, 01.02.2005, p. 65-77.

Research output: Contribution to journalArticle

Wang, Haiqing ; Vath, Gregory M. ; Kawamura, Akane ; Bates, Caleb A. ; Sim, Edith ; Hanna, Patrick E. ; Wagner, Carston R. / Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1. In: Protein Journal. 2005 ; Vol. 24, No. 2. pp. 65-77.
@article{dce8d3ffc6f94bcd8331a25dfe4fecbe,
title = "Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1",
abstract = "Human arylamine N-acetyltransferase 1 (NAT1) has been overexpressed in E. coli as a mutant dihydrofolic acid reductase (DHFR) fusion protein with a thrombin sensitive linker. An initial DEAE anion-exchange chromatography resulted in partial purification of the fusion protein. The fusion protein was cleaved with thrombin, and human rNAT1 was purified with a second DEAE column. A total of 8 mg of human rNAT1 from 2 l of cell culture was purified to homogeneity with this methodology. Arylamine substrate specificities were determined for human rNAT1 and hamster rNAT2. With both NATs, the second order rate constants (k cat/K mb) for p-aminobenzoic acid (PABA) and 2-aminofluorene (2-AF) were several thousand-fold higher than those for procainamide (PA), consistent with the expected substrate specificities of the enzymes. However, p-aminosalicylic acid (PAS), previously reported to be a human NAT1 and hamster NAT2 selective substrate, exhibits 20-fold higher specificity for hamster rNAT2 (k cat/K mb3410 μM -1 s -1 ) than for human rNAT1 (k cat/K mb 169.4 μM -1 s -1 ). p-aminobenzoylglutamic acid (pABglu) was acetylated 10-fold more efficiently by human rNAT1 than by hamster rNAT2. Inhibition studies of human rNAT1 and hamster rNAT2 revealed that folic acid and methotrexate (MTX) are competitive inhibitors of both the unacetylated and acetylated forms of the enzymes, with K I values in 50-300 μ range. Dihydrofolic acid (DHF) was a much poorer inhibitor of human rNAT1 than of hamster rNAT2. The combined results demonstrate that human rNAT1 and hamster rNAT2 have similar but distinct kinetic properties with certain substrates, and suggest that folic acid, at least in the non-polyglutamate form, may not have an effect on human NAT1 activity in vivo.",
keywords = "Arylamine N-acetyltransferase, Dihydrofolate, Folate, Methotrexate, NAT, p-aminobenzoic acid",
author = "Haiqing Wang and Vath, {Gregory M.} and Akane Kawamura and Bates, {Caleb A.} and Edith Sim and Hanna, {Patrick E.} and Wagner, {Carston R}",
year = "2005",
month = "2",
day = "1",
doi = "10.1007/s10930-004-1513-9",
language = "English (US)",
volume = "24",
pages = "65--77",
journal = "Protein Journal",
issn = "1572-3887",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1

AU - Wang, Haiqing

AU - Vath, Gregory M.

AU - Kawamura, Akane

AU - Bates, Caleb A.

AU - Sim, Edith

AU - Hanna, Patrick E.

AU - Wagner, Carston R

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Human arylamine N-acetyltransferase 1 (NAT1) has been overexpressed in E. coli as a mutant dihydrofolic acid reductase (DHFR) fusion protein with a thrombin sensitive linker. An initial DEAE anion-exchange chromatography resulted in partial purification of the fusion protein. The fusion protein was cleaved with thrombin, and human rNAT1 was purified with a second DEAE column. A total of 8 mg of human rNAT1 from 2 l of cell culture was purified to homogeneity with this methodology. Arylamine substrate specificities were determined for human rNAT1 and hamster rNAT2. With both NATs, the second order rate constants (k cat/K mb) for p-aminobenzoic acid (PABA) and 2-aminofluorene (2-AF) were several thousand-fold higher than those for procainamide (PA), consistent with the expected substrate specificities of the enzymes. However, p-aminosalicylic acid (PAS), previously reported to be a human NAT1 and hamster NAT2 selective substrate, exhibits 20-fold higher specificity for hamster rNAT2 (k cat/K mb3410 μM -1 s -1 ) than for human rNAT1 (k cat/K mb 169.4 μM -1 s -1 ). p-aminobenzoylglutamic acid (pABglu) was acetylated 10-fold more efficiently by human rNAT1 than by hamster rNAT2. Inhibition studies of human rNAT1 and hamster rNAT2 revealed that folic acid and methotrexate (MTX) are competitive inhibitors of both the unacetylated and acetylated forms of the enzymes, with K I values in 50-300 μ range. Dihydrofolic acid (DHF) was a much poorer inhibitor of human rNAT1 than of hamster rNAT2. The combined results demonstrate that human rNAT1 and hamster rNAT2 have similar but distinct kinetic properties with certain substrates, and suggest that folic acid, at least in the non-polyglutamate form, may not have an effect on human NAT1 activity in vivo.

AB - Human arylamine N-acetyltransferase 1 (NAT1) has been overexpressed in E. coli as a mutant dihydrofolic acid reductase (DHFR) fusion protein with a thrombin sensitive linker. An initial DEAE anion-exchange chromatography resulted in partial purification of the fusion protein. The fusion protein was cleaved with thrombin, and human rNAT1 was purified with a second DEAE column. A total of 8 mg of human rNAT1 from 2 l of cell culture was purified to homogeneity with this methodology. Arylamine substrate specificities were determined for human rNAT1 and hamster rNAT2. With both NATs, the second order rate constants (k cat/K mb) for p-aminobenzoic acid (PABA) and 2-aminofluorene (2-AF) were several thousand-fold higher than those for procainamide (PA), consistent with the expected substrate specificities of the enzymes. However, p-aminosalicylic acid (PAS), previously reported to be a human NAT1 and hamster NAT2 selective substrate, exhibits 20-fold higher specificity for hamster rNAT2 (k cat/K mb3410 μM -1 s -1 ) than for human rNAT1 (k cat/K mb 169.4 μM -1 s -1 ). p-aminobenzoylglutamic acid (pABglu) was acetylated 10-fold more efficiently by human rNAT1 than by hamster rNAT2. Inhibition studies of human rNAT1 and hamster rNAT2 revealed that folic acid and methotrexate (MTX) are competitive inhibitors of both the unacetylated and acetylated forms of the enzymes, with K I values in 50-300 μ range. Dihydrofolic acid (DHF) was a much poorer inhibitor of human rNAT1 than of hamster rNAT2. The combined results demonstrate that human rNAT1 and hamster rNAT2 have similar but distinct kinetic properties with certain substrates, and suggest that folic acid, at least in the non-polyglutamate form, may not have an effect on human NAT1 activity in vivo.

KW - Arylamine N-acetyltransferase

KW - Dihydrofolate

KW - Folate

KW - Methotrexate

KW - NAT

KW - p-aminobenzoic acid

UR - http://www.scopus.com/inward/record.url?scp=21044456766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044456766&partnerID=8YFLogxK

U2 - 10.1007/s10930-004-1513-9

DO - 10.1007/s10930-004-1513-9

M3 - Article

C2 - 16003948

AN - SCOPUS:21044456766

VL - 24

SP - 65

EP - 77

JO - Protein Journal

JF - Protein Journal

SN - 1572-3887

IS - 2

ER -